Post by account_disabled on Feb 20, 2024 8:47:23 GMT
Adverse effects A volunteer receives a vaccine in trials against COVID-19. Vaccines, like any medication, can cause side effects. One of the main problems facing researchers is the enhancement of antibody-dependent infection, better known as ADE . This is an unwanted reaction in which the generation of antibodies against an infectious agent, for example using a vaccine, results in much worse symptoms. This means that the disease is enhanced in case of infection by the virus. The mechanisms of ADE are still very little known and the good news is that it is quite rare. It has been described against respiratory syncytial virus and dengue virus. The bad news is that it has also been described in other coronaviruses, such as the feline infectious peritonitis virus, and coronaviruses that infect humans, such as those responsible for SARS and MERS.
Therefore, the possibility of ADE occurring is a real concern and is being actively evaluated in the various phases of development. Mainly in phase 3, where a considerable number of volunteers participate. 5. Large scale production A volunteer is injected with one of the first vaccines against COVID-19 REUTERS/Siphiwe Sibeko One of the main Middle East Phone Number List challenges that we will face if an effective vaccine against the coronavirus is obtained will be its mass production on a large scale so that it reaches the largest possible part of the world's population. We are talking about producing billions of doses. This is without taking into account that many of the vaccines under study require two doses per individual.
Furthermore, another added problem would be to massively produce sufficient doses without affecting the production of other important vaccines. 6. Vaccine distribution Vaccine against COVID-19 Let's imagine that an effective vaccine against SARS-CoV-2 is developed and produced on a large scale. The next problem would be its efficient delivery to billions of people in the world. There is no point in having a vaccine if it does not reach the end user. Achieving efficient global distribution poses significant logistical problems. Vaccine manufacturing companies, the governments of different countries and transport companies should work in coordination and agree. Generally, most vaccines should be kept refrigerated at 2°C to 8°C. For this reason, one of the main challenges to overcome would be not breaking the cold chain.
